MALLINCKRODT’S STRATATECH COMPANY AWARDED $26 MILLION IN ADDITIONAL BARDA FUNDING FOR PEDIATRIC STUDIES OF STRATAGRAFT® SKIN TISSUE IN THERMAL BURNS da Admin | Ott 18, 2018 | Other“https://www.prnewswire.com”
MALLINCKRODT’S STRATATECH COMPANY AWARDED $26 MILLION IN ADDITIONAL BARDA FUNDING FOR PEDIATRIC STUDIES OF STRATAGRAFT® SKIN TISSUE IN THERMAL BURNS da Admin | Ott 18, 2018 | Altro“https://www.prnewswire.com”
MARKER THERAPEUTICS: A SAFER AND POTENTIALLY MORE EFFECTIVE CAR-T ALTERNATIVE da Admin | Ott 18, 2018 | Business“https://seekingalpha.com”
MARKER THERAPEUTICS: A SAFER AND POTENTIALLY MORE EFFECTIVE CAR-T ALTERNATIVE da Admin | Ott 18, 2018 | Business“https://seekingalpha.com”
AVEXIS ASKING FDA, EU TO APPROVE AVXS-101 AS 1ST GENE THERAPY FOR SMA TYPE 1 da Admin | Ott 18, 2018 | Regulatory“https://smanewstoday.com”